Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation
stevepb / Pixabay

Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Poseida Therapeutics, Inc. recently announced that the company's investigational product candidate P-BCMA-101 has been granted Orphan Drug Designation from the US…

Continue Reading Experimental Treatment for Multiple Myeloma Earns Orphan Drug Designation

New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…

Continue Reading New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

New Bill Could Allow Easier Access to Complex Rehabilitation Technology for Rare Disease Patients

H.R. 2408 H.R. 2408 is a new piece of federal legislation otherwise known as the "Ensuring Access to Quality Complex Rehabilitation Technology Act." Essentially, this act creates a new category…

Continue Reading New Bill Could Allow Easier Access to Complex Rehabilitation Technology for Rare Disease Patients

Singer Charity Sunshine Tillemann-Dick Passed Away From Pulmonary Arterial Hypertension at Age 35

According to a story from radio.wpsu.org, soprano singer Charity Sunshine Tillemann-Dick recently passed away at the young age of 35 because of pulmonary arterial hypertension, a rare condition of increased…

Continue Reading Singer Charity Sunshine Tillemann-Dick Passed Away From Pulmonary Arterial Hypertension at Age 35
Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Recommended for Marketing Approval in the EU
pixel2013 / Pixabay

Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Recommended for Marketing Approval in the EU

According to a story from Market Screener, the biopharmaceutical company Alexion Pharmaceuticals has recently announced some encouraging news regarding the status for ravulizumab (marketed as ULTOMIRIS) in the EU. The…

Continue Reading Possible Treatment for Paroxysmal Nocturnal Hemoglobinuria Recommended for Marketing Approval in the EU

Evidence Suggests The Spinal Muscular Atrophy Gene Therapy Could Help all Patients Regardless of Severity

According to a story from BNN Bloomberg, data from three studies suggest that Zolgensma, a gene therapy for spinal muscular atrophy developed by Novartis, could be useful to all patients…

Continue Reading Evidence Suggests The Spinal Muscular Atrophy Gene Therapy Could Help all Patients Regardless of Severity
Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It
Source: Pixabay.com

Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It

Cedric Rutland, a pulmonologist at Pacific Pulmonary Medical Group has shared his experience, research, and thoughts on cognitive bias in an effort to spread awareness for the issue, and hopefully,…

Continue Reading Cognitive Bias in Idiopathic Pulmonary Fibrosis Management and Steps We Can Take to Avoid It

First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA

Transthyretin-Mediated Amyloidosis Cardiomyopathy The FDA has just approved the very first treatment for hereditary or wild-type transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).  ATTR-CM is a rare disease that occurs when amyloids, an…

Continue Reading First Ever Treatment for Transthyretin-Mediated Amyloidosis Cardiomyopathy Approved by FDA